Puneet Varma (Editor)

JWH 200

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
CAS Number
  
103610-04-4

ChemSpider
  
8221134

Formula
  
C25H24N2O2

PubChem CID
  
10045570

UNII
  
9HN5J913P3

Molar mass
  
384.469 g/mol

JWH-200

Legal status
  
AU: S9 (Prohibited)CA: Schedule IIDE: Anlage II (Prohibited)US: Schedule I

JWH-200 (WIN 55,225) is an analgesic chemical from the aminoalkylindole family that acts as a cannabinoid receptor agonist. Its binding affinity, Ki at the CB1 receptor is 42 nM, around the same as that of THC, but its analgesic potency in vivo was higher than that of other analogues with stronger CB1 binding affinity in vitro, around 3 times that of THC but with less sedative effect, most likely reflecting favourable pharmacokinetic characteristics. It was discovered by, and named after, Dr. John W. Huffman.

Contents

Australia

JWH-200 is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

United States

The US DEA temporarily declared JWH-200 a schedule I controlled substance on 1 March 2011 through 76 FR 11075, and permanently instated the same schedule on 9 July 2012 in the Section 1152 of the Food and Drug Administration Safety and Innovation Act. As of 16 July 2015, the drug is a controlled substance in Canada.

References

JWH-200 Wikipedia


Similar Topics